Darunavir is a next-generation protease inhibitor that demonstrates potent in vitro activity against wild type strains of HIV type-1, as well as against numerous strains resistant to available protease inhibitors. Numerous trials conducted in naïve and in the treatment-experiencedHIV-infectedindividualshavesignificantlydemonstratedgreatervirologicalsuppressionwhendarunavirwas added to an optimized background treatment compared with a control protease inhibitors. The drug is taken as two 400 mg tablets once daily plus 100 mg of ritonavir in naïve patients, while is taken as two 300 mg tablets plus 100 mg of ritonavir twice daily in experienced patients.Darunavirhasahighgeneticbarrierandhasadistinctresistanceprofile.Darunavirresistance-associatedmutationshavebeen definedasV11I,V32I,L33F,I47V,I50V,I54L/M,T74P,L76V,I84V,andL89V.Themajoradverseeffectsofdarunavirtherapyare nausea, diarrhea and rash; and as others protease inhibitors, increase of triglycerides and total cholesterol.
Introduction
In 1983 the human immunodeficiency virus type 1 (HIV-1) was recognized as the primary cause of the acquiredimmunodeficiencysyndrome(AIDS).After 25 years, HIV infection remains a significant cause of morbidity and mortality. 1 Major advances in HIV treatment have revolutionized patient care and prolonged survival, with the result that HIV infection can now be effectively managed as a chronic disease, at leastintheindustrializedcountries.Particularly,combined antiretroviral therapy (cART) has completely changed the course of HIV infection, but current drugs do not eradicate the virus and lifelong treatment is necessary. 2, 3 The goals driving the decision to initiate cART therefore are to reduce HIV-related morbidity and prolong survival, improve quality of life, restore and preserve immunologic function, maximally and durably suppress viral load, and prevent vertical HIV transmission. 4 At present there are 23 approved antiretroviral drugs, in six mechanistic classes with which to design combination regimens. These six classes includethenucleoside/nucleotidereversetranscriptaseinhibitors(NRTIs),nonnucleosidereversetranscriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), CCR5 antagonists, and integrase inhibitors (INIs).
The initial selection of an antiretroviral regimen depends on the patient's characteristics, comorbidities, and drug susceptibility of the patient. Particularly, transmission of resistant variants in developed countries ranges from 5% to 20%. 5 The selection is additionallyinfluencedbyfactorslikepillburden,frequency of dosing, drug interactions, poor adherence, tolerability, and short-and long-term adverse events profiles, and these treatment challenges continue to influencetheuseofthecART.Potentialforemergence of resistance during therapy and subsequent treatment options may also affect the design of an initial regimen. 6 Despite the availability of cART, a need still exists to develop antiretroviral agents that can sustain virological inhibition and have good tolerability in a broad range of HIV-infected patients. The darunavir (DRV)hasbeendevelopedtomeetthisneed.
Darunavir
DRVisanoralnon-peptidicHIV-1PIsthatisused, together with a low boosting dose of ritonavir (DRV/r),aspartofancARTregimeninnaïveand treatment-experienced patients with HIV infection, approvedbytheFoodandDrugAdministrationon June 23, 2006 initially for experienced then naïve patients. 7 It is a second-generation PIs, designed specifically to overcome problems with the older generation PIs: severe side effects and drug toxicities, higher therapeutic doses due to peptide-like character, and the emergence of drug resistance. 8 Pharmacodynamics DRV, like all PIs, selectively inhibits the cleavage of HIV gag and gag-pol polyproteins. Inhibition renders the viral particles unable to reproduce or infect. 9 Inactivation of the protease enzyme is achieved through competitive binding of the enzyme ina"lockandkey"manner.PIsactasfalse"keys" that disrupt protease activity through binding to the activeenzymesite.DRValsoinhibitsdimerization of HIV-protease, thus inhibiting proteolytic activity and subsequent HIV-1 replication. 10 Themajorityof PIscontainsubstantialpeptide-likefeatures.DRVis a nonpeptidic analogue of amprenavir, with a critical change at the terminal tetrahydrofuran (THF) group. Like amprenavir, DRV contains a sulphonamide group and instead of a single THF group, 2-THF groups are fused in the DRV compound to form a 2-THF moiety. 11, 12 This structural change leads to increased hydrogen bond interactions with more regions of the protease enzyme and an associated increase in binding energy. 13 Conformational analysis has demonstrated that the agent is able to form a highly stable complex with protease, largely due to conformational flexibility and backbone interactions, which leads to less sensitivity of the biological activity and which results in continued enzyme inhibition in the presence of several mutations.
14 With numerous hydrogen bonds, 2-THFwasshowntocloselyandtightlybindtothe backboneatomsoftheS2sub-siteoftheprotease. Such tight interactions were consistently observed with mutant proteases and might therefore account for the unusually high resistance profile of DRV. Optimization attempts of the backbone binding in other sub-sites of the enzyme, through rational modificationsoftheisostereortailormadeP2ligands, led to equally impressive inhibitors with excellent resistanceprofiles.
Pharmacokinetics
DRV is rapidly absorbed after oral administration, generally reaching peak plasma concentrations within 2.5-4 hours. Compared with a single dose of DRV 600mgalone,DRV/r600/100mgtwicedailyhadan increasedabsoluteoralbioavailability(from≈37%to 82%). 15 ThebioavailabilityoforalDRVisincreased byabout30%whentakenwithfood.Thetypeofmeal does not affect exposure. 16 Steadystatusisreachedat 72hours.ProteinbindingofDRVishigh,atabout95%, bound primarily to plasma α 1 -acid glycoprotein.
DRV is primarily metabolizedand eliminatedby the hepatic CYP system and almost exclusively by isoenzyme CYP3A4. Total plasma concentration of DRV in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) hepatic impairment was comparable with that in healthy subjects. However, the concentration of unbound DRV was approximately55%(Child-PughClassA)and100% (Child-PughClassB)higher,respectively.Theclinical relevance of this increase is unknown, but caution should be used in this patient group. 17 In an analysis of pharmacokinetic data from treatmentexperiencedpatientsinthePOWER1and3studies, therewerenodifferencesinDRVexposureinpatients co-infectedwithhepatitisBorCorpatientswithout co-infection.
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In patients with renal impairment, no special precautionsordosageadjustmentsarerequired,infact analysis showed that the pharmacokinetics of DRV werenotsignificantlyaffectedinHIV-infectedpatients with moderate renal impairment (CrCl between 30-60mL/min). 16 ThepharmacokineticsofDRV/rin74treatment-experiencedpediatricpatients,aged6to17yearsand weighingatleast20kg,showedthattheadministered weight-based doses of DRV/r resulted in DRV exposure comparable to that in adults receiving DRV/r 600/100 mg. Population pharmacokinetic analysis in HIV-infected patients showed that DRV pharmacokinetics are not considerably different in the agerange(18to75years)evaluatedinHIVinfected patients. However, only limited data were available inpatientsabovetheageof65year,thencautionis recommended in this group. 19, 20 The pharmacokinetics of DRV/r in 18 patients showed that the median concentration in cerebrospinal fluid (CSF) was 56.9 ng/mL, while the median total plasmaconcentrationwas4094ng/mLandthemedian unboundplasmaconcentrationwas542ng/mL(DRV tends to bind with blood proteins, which interferes with abilitytocrosstheblood-brainbarrier).DRVconcentrationsinCSFalsoexceededtheIC50forwild-type HIV,withamedianlevel20.7timestheIC50.DRV CSFconcentrationsalsohadapositivecorrelationwith total plasma concentrations, but the association with unboundplasmalevelswasnotsignificantlystronger. Sixty-twopercentofDRVrecipientshadundetectable plasmaviralloadand90%hadundetectableCSFviral load.DRVisinthetherapeuticrangeforinhibitionof wild-type HIV and should contribute to control HIV replication in the nervous system as a component of effective antiretroviral therapy.
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ExposuretoDRV/rwasslightlyhigherinwomen than in men, but this is not considered clinically relevant. 16 Adequate studies of DRV/r in pregnant women have not been performed and the drug should only be used in pregnancy if the potential benefit justifiesthepotentialrisk.
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Table1summarizedruginteractionsofDRVwith antiretrovirals and other drugs common use in clinical practice. 
Efficacy
DRV/r600/100mg,hasdemonstratedsustainedefficacy and good safety in patients with a broad range of treatment experience. 22 On the basis of the results intreatment-experiencedpatientsoncedailyDRV/r was tested in HIV-naïve population. 23 The availabledatahighlightthatDRV/risrecommendedfor treatment-naïve and treatment-experienced adults and adolescents. 4 Treatment-naïve patients An initial cART regimen should be potent, durable, able to prevent or delay the onset of drug resistance and should also have good tolerability and a convenient dose schedule. On the basis of the results from POWER(PerformanceOfTMC114/rWhenevaluated intreatment-experiencedpatientswithPIResistance) studies in treatment experienced patients, once-daily DRV/r800/100mgwasselectedforpatientswithno previous treatment experience. The suitable of oncedaily dosing in this population is supported by the long half-life of DRV in the presence of ritonavir. ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMinedInnaïveSubjects)isastudyassessingthe efficacyandsafetyofDRV/r800/100mgascompared with lopinavir/ritonavir (LPV/r) in treatment-naïve HIV-1 infected patients over 192 weeks. It is a randomized, phase III, open-label trial conducted across 26countries. 23, 24 Treatment-naïve HIV-1 infected adult patients,withplasmaHIV-RNAatleast5000copies/mL wererandomizedtoreceiveeitherDRV/r800/100mg orLPV/r800/200mgtotaldailydose.Inaddition,all patients received a fixed combination, tenofovir and emtricitabine.
Theprimaryobjectiveofthetrialwastodemonstratenon-inferiorityofDRV/r800/100mgascom-paredwithLPV/r800/200mginvirologicresponse at 48 weeks. Secondary objectives included evaluation of virologic and immunologic parameters over 192weeks,evaluationofsafetyandtolerabilityand in the event of non-inferiority testing for superiority ofDRV/roverLPV/r.
At weeks 48, 84% of DRV/r and 78% of LPV/r patientshadaconfirmedvirologicresponseofHIV-1 RNA less than 50 copies/mL, demonstrating noninferiority of DRV/r as compared with LPV/r. The median change from baseline in CD4 cell count at week48wassimilarbetweenthegroups.Inpatients withhighbaselineHIV-RNA(100000copies/mL), LPV/rresponserates(67%)werelowerversusDRV/r (79%),resultinginastatisticallysignificantlyhigher responseratewithDRV/r. Atweek96,79%ofpatientsreceivingDRV/rvs. 71% of patients receiving LPV/r had a confirmed a viral load undetectable. The estimated difference in responseforDRV/rvs.LPV/rwas8,4%,demonstratingnon-inferiorityofDRV/rrelativetoLPV/r.Furtheranalysisshowed,forthosewithabaselineCD4 cellcountlessthan200cells/µl, that the response rate washigherintheDRV/rarmthanintheLPV/rarm (79% vs. 65%). Response rates between arms were not significantly different for patients with HIV-1 RNAlessthan100000copies/mLorCD4cellcount atleast200cells/µl at baseline. 24 These results demonstrate that DRV/r together withafixedNRTIsbackgroundregimenwashighly effective for treatment-naïve patients. Furthermore, 92%ofDRV/rpatientswhohadanundetectableviral load at week 48 remained undetectable at week 96, providing evidence of the continued potency in naïve patients.
induction and maintenance This treatment strategy involves starting with a highly potentcombinationregimenforthefirstsixtotwelve months (the induction regimen), then subtracting some of the drugs once most of the virus population has been eliminated (the maintenance regimen) and DRV/r,couldbeagoodoption. 25 IntheMONET,the firstDRVmonotherapytrial,theresearchersrecruited 256 Europeans with a viral load 50 copies for at least6monthswhiletakingastandardNNRTIregi-men(43%)orPIregimen(57%). 26 No one could have DRVexperience,andnoonecouldhaveahistoryof virologicfailure.TheMONETteamrandomized127 peopletoswitchto800/100mgofDRV/roncedaily alone and 129 to start once-daily DRV/r plus two NRTIs. Most study participants were white (91%), andmost(81%)weremen.MedianCD4countstood at575andmedianageat43years.Peoplerandomized to monotherapy had taken antiretrovirals longer (average7.4versus6.4years),andmoreofthemhad hepatitis C virus infection (19% versus 11%). Nine people in each treatment group stopped taking their assigned regimen. No new or unexpected treatmentrelated problems arose during the trial.
Defining failure as consecutive viral loads 50 copies, the investigators calculated a 48-week virologicresponserateof86.2%withmonotherapyand 87.8%withtripletherapyinaper-protocolanalysis that excluded 10 patients with protocol violations and counted drug switches as failures. In an intent-totreat analysis that included the 10 protocol violations, response rates were almost identical 84.3% with monotherapyand85.3%withstandardtherapy (Fig.2) . Andinananalysisthatallowedswitching,response rateswere93.5%withmonotherapyand95.1%with tripletherapy.Allofthesecomparisonsindicatedthat DRV/rmonotherapyisnotinferiortoDRV/rplustwo nucleosides in people who start one of these regimens with a viral load 50 copies. Eleven people in the monotherapygroupand7inthetriple-therapygroup hadtwotransientviralloadreadingsabove50copies, and2peopleineachgrouphadasustainedviralload rebound above 400 copies. The investigators attributed most temporary or sustained rebounds to poor adherence or to emergence of other illnesses that may affect HIV load.At the last study visit, 124 of 127 people randomized to monotherapy and 126 of 129 randomizedtotripletherapyhadaviralloadunder50 (97.6%and97.7%). Arribas and coworkers searched for resistance mutations any time someone's viral load rose above 50copies.Mostofthese50-plusreadingsweretransientblips.Asalreadynoted,peopleinthemonotherapygrouphadmoreblips,aresultreflectingfindings inrandomizedtrialsofLPV/rmonotherapy.Alltold, the MONET team had successful genotypes on 22 people taking monotherapy and 13 taking triple therapy.Anewresistancemutationemergedinonlyone personineachstudygroup.TheM184Vlamivudine/ emtricitabinemutationandoneprimaryPImutation arosein1persontakingDRVplustwoNRTIs;one primary PI mutation and one DRV-related mutation evolved in a person on monotherapy. Neither of the two people with new PI mutations had phenotypic evidenceofdecreasedviralsusceptibilitytoDRV.
Compared with the MONET trial, a French trial of the same maintenance tactic proved less convincing for three reasons: in one of two 48-week analyses,DRV/rmonotherapywas"notnoninferior" to DRV/r triple-therapy maintenance; there were threevirologicfailuresinpeopletakingDRV/rmonotherapy and none in the standard-therapy arm; and virologic response analyses used a viral load thresholdof400copiesinsteadof50copies. 27 TheFrench MONOItrial(ANRS136)enrolled242peoplewith a viral load 400copiesforatleast18monthsand fewerthan50copiesatentry.NoonehadtakenDRV/r before, and no one had a record of virologic failure.
Duringan8-weekinductionphase,everyonetook DRV/r(600/100mgtwicedaily)plustwoNRTI.The 225 people who maintained viral suppression were randomizedtocontinuetwice-dailyDRV/rplustwo NRTI (n = 113) or to switch to twice-daily DRV/r monotherapy (n = 112). Three quarters of MONOI participants were men. Median age was about 46 years, and starting CD4 counts were 582 in the triple-therapyarmand585inthemonotherapygroup. While73%inthetriple-druggroupenteredthetrial takingaPI,64%inthemonotherapyarmweretaking aPI-basedregimen.About20%ineachgroupwere takingaNNRTI-basedcombination,andtherestwere takingthreeNRTI.
TheMONOIteamdefinedfailureasconsecutive viral loads 400copiesortreatmentmodificationor discontinuation. In a per-protocol analysis, 99% in the triple-drug arm and 94.1% in the monotherapy arm met those response criteria by week 48. Those resultsindicatedthatDRV/rmonotherapyisnotinferiortoDRV-basedtripletherapyinpeoplelikethose in this trial.
The goal in both studies was to show non-inferiority oftheDRV-onlyregimen.Bothstudiesdidso,although with some differences in the details.
IntheMONETtrialtheprimaryendpointwasthe proportion of patients whose viral load remained suppressedattheendofthefirst48weeksofthe96-week study.TheDRValoneregimenwasconsiderednoninferiorifthedifferencewaslessthan12%.
In the intent-to-treat population 85.3% of the patients on three drugs maintained viral suppression, compared with 84.3% of those on DRV alone. The estimated difference of 1% had a 95% confidence interval whose lower limit was minus 9.9%-well withintheminus12%cut-offfornon-inferiority.The per-protocol results were similar and also showed non-inferiority.
In the MONOI the per-protocol population, only 1%ofthosegettingtripletherapyfailed,wherefailure was defined as two consecutive levels above 400 copies of HIV RNA per millilitres of plasma. Thatcomparedwith5.9%ofthosetakingDRVonly.
The90%confidenceintervalofthe4.9%difference had a lower bound of minus 9%, which was within thespecifiedminus10%cut-offfornon-inferiority.
In the intent-to-treat population, the results were similar,butthelowerboundoftheconfidenceintervalfelloutsidethenon-inferiorityconfidenceinterval. The results of the two studies combined suggest that DRVrepresentsaviablealternativetostandardtriple therapy.
Treatment-experienced patients POWER 1 and 2 are randomised, multina-tional (POWER 1: Australia, Brazil, Canada, Europe; POWER2:Argentina,USA),144-weekphaseIIB trialscomparingtheefficacyandsafetyofDRV/rwith that of currently available in treatment-experienced HIV-1 infected patients. The first 24 week constitutedadose-findingphase:patients,aged18years, were HIV-infected adults with prior use of NRTIs, NNRTIs and one or more PIs for at least 3 months (prior enfuvirtide use was allowed), with plasma HIV-RNA  1000 copies/mL and one or more primary PIs mutation, receiving a stable PI-containing regimen. Investigators selected an Optimized Background Therapy (OBT) for each patient based on genotypic resistance and treatment history (NNRTI were excluded) and then patients were randomized toreceiveoneoffourDRV/rdosesortheirinvestigator-selectedcontrolPI-basedregimen(controlPIs group) from baseline.The dose DRV/r 600/100 mg twice daily demonstrated the highest virological and immunological response.
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After the primary 24-week efficacy analysis, patientsinthecontrolPIarmcontinuedtheirassigned treatmentwhereasallpatientsreceivingDRV/rwere switched to DRV/r 600/100 mg twice daily for the longer-term, open-label phase of the randomizedcontrolledtrials:sothecombined48-,96-and 144-week subgroup analyses included only those patients who received boosted DRV/r 600/100 mg twice daily. [30] [31] [32] At week 144, 48 (37%) patients in the DRV/r 600/100 mg twice daily group and 11 (9%) patients in the PIs group achieved HIV-RNA  50copies/mL.Anincreaseof1 log 10 HIV-RNA reductionwasachievedby67(51%)patientsinthe DRV/r600/100mgtwicedailygroupand12(10%) patientsinthePIgroup.ThemedianCD4cellcount increasedfrombaselineby97cells/mm 3 intheDRV/r 600/100mgtwicedailygroupand4cells/mm 3 in the PIgroup. 32 InconclusionPOWERstudiesconfirmthatDRV/r 600/100mgtwice-dailyhaslong-termefficacyandis a treatment option in treatment-experienced patients.
TheefficacyresultsofPOWER1and2arecon-firmedbydatafromalarge,non-randomizedopenlabel analysis known as POWER 3. At 24 weeks, 65%ofpatientsachievedareductioninviralloadof 1 log 10 ormoreversusbaseline,and40%ofpatients reached 50 HIV-RNA copies/mL. These results corroboratePOWER1andPOWER2studies.
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In TITAN (TMC114/r In Treatment-experienced pAtients Naïve to lopinavir) study, the efficacy and safety of DRV/r were assessed in lopinavir-naïve patients who had substantially less treatment experiencethandidthoseinthePOWERtrials. 22 The aim of this study was to show non-inferiority of DRV/r 600/100 mg twice daily compared with lopinavirritonavir 400/100 mg twice daily, in terms of virological response, with both agents given in addition toanindividuallyOBT.Lopinavir-ritonavirwaschosenascomparatorbecauseofitsefficacyandsafety in PI-experienced patients in several randomized controlled trials.
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It is a continuing, international, randomized, controlled, open-label, 96-week phase III trial. Patients aged 18yearswhohadreceivedprevioustreatment with HAART for at least 12 weeks, lopinavir naïve, were eligible for study entry. Patients were assigned toanOBT,includingatleasttwoantiretroviraldrugs (NRTI with or without NNRTI) and, then, were randomized in a 1:1 ratio to receive DRV/r 600/100 mg twicedailyorLPV/r400/100mgtwicedaily.
The results showed that DRV/r was not only not-inferior to LPV/r, as determined by the primary endpoint of less than 400 copies/mL of HIV-RNA at week 48 but was also significantly better than boosted lopinavir at 48 and 96 weeks. In fact more patients in the population in the DRV/r group than in the lopinavir group had a viral load of 400 copies/mL at week 48 (77% vs. 68%; mean differenceof9%). 22 Similarresultswererecordedfor thisendpointinthepopulationat96weeks. 24 In addition significantly more patients in the DRV/r group thaninthelopinavirgroup(71%vs.60%)achieved a plasma viral load 50copies/mLatweek48.The proportion of patients achieving a viral load reduction from baseline of 1 log 10 copies/mLwerehigher intheDRV/rgroupthaninthelopinavirgroup.The meanincreaseinCD4cellcountwasnotsignificantly different between treatment groups.
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In conclusion DRV/r at a dose of 600/100 twice dailyhasdemonstratedsustainedefficacyinpatients with a broad range of treatment experience.
In the TRIO trial 36 French researchers assessed the safety and efficacy of an antiretroviral regimen containingraltegravir,theNNRTIetravirineandthe DRV/r in treatment-experienced HIV patients with multidrug-resistant virus. This Phase II multicenter trial enrolled 103 treatment-experienced patients. Most(88%)weremen.Participantshadplasmaviral load 1000copies/mL,hadnotpreviouslyusedthe drugs under investigation, had a history of virological failurewhileonNNRTI,andhadmultipleHIVmutationsconferringresistancetomultipledrugclasses.At baseline, the median viral load was 4 log 10 copies/mL and the median CD4 cell count was 255 cells/mm 3 (nadir79cells/mm 3 ). The median time since starting HIVtreatmentwas13years,and44%hadahistoryof AIDS-defining events. Participantshad a median of 4primaryPIresistancemutations,6NRTIresistance mutations,and1NNRTIresistancemutation.Almost all(96%)had1-3DRVresistancemutationsand65% had 1-3 etravirine resistance mutations. Background regimensincludedNRTIandtheadditionentryinhibitor enfuvirtide, whenever possible. The regimens of 83% of patients included NRTI (with a median genotypic sensitivity score =0.5);14includedenfu-virtide as part of their regimen, of whom 12 were enfuvirtide-naive. The primary endpoint was the proportion of patients with undetectable viral load (50 copies/mL) at week 24. The results showed that57patients(55%)hadundetectableviralloadat week4;91patients(88%)hadundetectableviralload atweek12.Atweek24,93patients(90%)hadviral load 50 copies/mL and 98 (95%) had viral load 400copies/mL.ThemeanreductioninHIVRNA was 2.4 log 10 . The median CD4 cell count increase was99cells/mm 3 . Regimens containing the 3 study drugs were generally well tolerated. These findings show the potentially significant advantages of using 3 fully active oral drugs in treatment-experienced patients with multidrug-resistant HIV.
Treatment of children and adolescent
Combination antiretroviral therapy is recommended for all infants, children, and adolescent who are treated with antiretroviral agents. The current US and PENTA guidelines for using antiretrovirals in HIV-infected children are based largely on preliminary pediatric data and on studies in adult patients.
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UnderstandingappropriatedosingofDRV/rinchildren is important because these drugs have proved highly potent in adults with and without antiretroviral experience.
DELPHI (DRV EvaLuation in Pediatric HIVInfected, treatment-experienced patients; TMC114-C212) is a phase II trial designed to determine the appropriate DRV/r dose for treatment-experienced, HIV-1-infected children and adolescent aged 6-17years,andtoevaluatethelong-termsafetyand efficacyoftherecommendedpediatricdose.
38 DRV/r 600/100 mg twice daily as a body-weight-adjusted dose is indicated for this pediatric patient population; the approval was based on the 24-week results of DELPHI. This trial included treatment-experienced HIV-1 infected patients aged 6-17 years, with body weight at least 20 kg, HIV-RNA greater than 1000copies/mLandstableCD4.Patientswererandomized in a 1:1 ratio to receive either the weightadjusted,adult-equivalentdoseofDRV/r600/100mg twice-daily.(groupA,DRV9-15mg/kgandritonavir 1,5-2,5mg/kgtwice-daily)ora20-33%higherdose of DRV/r twice-daily (group B, DRV 11-19 mg/kg and ritonavir 1,5-2,5 mg/kg twice-daily). Once the dose was selected all part I patients not on the selected dose were switched to receive it at a planned visit and all patients were scheduled to continue in part II. PartIIevaluatedthesafetyandefficacyofDRV/rat theselecteddoseover48weeks.Allpatientsreceived DRV/r twice daily plus OBT. On the basis of the resultsofpartIofthistrial,therecommendedDRV/r doses for treatment-experienced, HIV-infected childrenandadolescentwithabodyweightof20-50kg areDRV11-19mg/kgandritonavir1,5-2,5mg/kg twicedaily.DRV/rtreatmentwasassociatedwithat least a 1 log 10 reductionfrombaselineinHIV-RNA for almost two-thirds of patients, and undetectable HIV-1 RNA (50 copies/mL) for almost half of all patients at week 48. Higher response rates wereobservedinyoungerpatients(6-12years)versus older patients (12-17 years) . This difference is thought to be attributable to the greater antiretroviral treatment experience and higher degree of drug resistance in adolescent patients compared with children under12yearsold.
In treatment-experienced children and adolescents,theresearchersconclude,DRV/rshowedcomparable exposure to adults with appropriate dose selection, favorable safety and tolerability, improved bodyweightandsignificantvirologicresponse.They proposethatDRV/risavaluabletherapeuticoption for this population.
Safety and tolerability
Tolerability data on DRV/r are available from all studies. [22] [23] [24] [26] [27] [28] [29] [30] [31] [32] [33] 39 ThesafetyanalysisinthePOWER study adverse events reported with an incidence of 10% or greater in patients receiving DRV/r were diarrhea(20%),nausea(18%),headache(15%),rhinopharyngitis (14%), fatigue (12%), upper respiratorytractinfection(12%)andherpessimplex(12%). IncidenceofadverseeventsintheDRV/rgroupswere mostly lower than or similar to those of the control PIs group; in particular diarrhea, nausea and headachehadalowerincidenceintheDRV/rgroup.The incidence of herpes simplex infection was greater in theDRV/rthanthecontrolPIsgroupandthereason for this difference remains unclear. The most common laboratory abnormalities were increased triglycerides, increased pancreatic amylase and lipase (no cases of clinical pancreatitis were observed) and increased total cholesterol.
In TITAN study, DRV/r was generally safe and well tolerated, with few treatment discontinuations. In addition gastrointestinal adverse events were more frequent in lopinavir/ritonavir than DRV/r patients. The incidence of rash was similar in the two treatment groups. Triglyceride increase were more frequentwithlopinavir/ritonavirthanDRV/r,whichmay be related to the higher daily dose of ritonavir with lopinavir/ritonavir.
In ARTEMIS study, most adverse events were grade1or2,anddiscontinuationduetoadverseevents were infrequent. The most common adverse events (regardless of severity and causality) were diarrhea, nausea, headache, upper respiratory tract infection, rhinopharyngitis, abdominal pain, vomiting, and cough. The overall incidence of laboratory abnormalities was comparable for DRV/r and lopinavir/ritonavir treatmentgroups.Meanincreaseintriglyceridesandtotal cholesterol were more pronounced with lopinavir/ ritonavirthanwithDRV/r.
Safety results of the week 48 analysis of DEL-PHI demonstrated a favorable overall tolerability profile for DRV/r in treatment-experienced pediatricpatients.Inadditionanimportantclinicalfinding wasthepositiveeffectofDRV/rtreatmentongrowth parameters.
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Dosing and administration
In treatment naïve patients, the recommended dosage is DRV/r 800/100 mg once-daily, while in treatment-experiencedpatientsisDRV/r600/100mg twice-daily.
Recommended dose for treatment-experienced pediatric patients (6 to 17 years of age) for DRV/r is based on body weight: 20-30 kg, 375/50 mg; 30-40 kg, 450/60 mg and 40 kg, 600/100 mg, always twice daily.
ThereareinsufficientdataontheuseofDRV/rin children less than6 years of age or less than 20 kg bodyweight.Hence,DRV/risnotrecommendedfor use in this group.
DRV is metabolized by the hepatic system. No dose adjustment is recommended in patients with mild(Child-PughClassA)ormoderate(Child-Pugh ClassB)hepaticimpairment,however,DRVshould be used with caution in these patients. No pharmacokinetic data are available in patients with severe hepatic impairment. Severe hepatic impairment could result in an increase of DRV exposure and a worseningofitssafetyprofile.Thereforeitmustnot be used in patients with severe hepatic impairment (Child-PughClassC).
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Resistance Several studies have looked at the prevalence of DRV-associated mutations in various populations. ThemutationsassociatedwithDRVareV11I,V32I, L33F, I47V, I50M, I54M, T74P, L76V, I84V, and L89V. 40 To estimate to what extent DRV might be effectiveinpatientsfailingdistinctPIsinaclinical setting,thegenotypicresistancescoresforDRVwere examined in a large clinical HIV-1 drug resistance database.All clinical specimens from HIV-infected patientsfailingPIs-basedregimensreferredfordrug resistancetestingbetween1999and2007toarefer-encecentreinMadridwereanalyzed.Atotalof1021 genotypes from patients failing lopinavir (39.2%), nelfinavir (28.1%), saquinavir (14.5%), indinavir (13.7%), atazanavir (6.6%), fosamprenavir (5.3%), and tipranavir (1.1%) were identified. The prevalenceofmajorDRVresistancemutationswas:I50V 2.1%, I54M 1.3%, L76V 2.7%, and I84V 14.5%. ForminorDRVresistancemutations,therateswere: V11I3.3%,V32I3.9%,L33F11%,I47V2.1%,I54L 2.3%,G73S12.8%,andL89V2.4%.Overall,6.7% (n =68)ofthegenotypeshad3ormoreDRVresis-tance mutations, which corresponded to a mean total numberofPIsresistancemutationsof12.3±1.9.In the multivariate analysis, prior fosamprenavir failure, prior saquinavir failure, the total number of PI resistance mutations, and the number of prior PIs used were all independently associated with having more DRV resistance mutations. 41 In another study of treatment-experienced individuals, patients harboring viruses with amprenavir-specific resistance profiles, such as I50V or V32I + I47V, failed on DRV/r-containing regimens. These key amprenavir mutations were also selected at the time of failure, suggestingtheirimpactonDRVefficacy. 42 However this data are not confirmed by other authors. 43 Picchio and colleagues predicted phenotypic sensitivity to DRV, using over 56,000 sample genotypes with differentlevelsofPIsresistance,fromtheVircodatabase from 2004-5. 44 Clinical and/or biological cutoffsusingupperandlowerlevelsforeachPI(3.4and 99.6 for DRV) were used to determine the relative sensitivitytoDRV,definedasmaximal,reduced,and minimalsensitivity.DRVshowedalowproportionof samples(5%)withminimalandreducedresponses. Recent study evaluate changes in 47 HIV-infected patientsfailingatipranavir/r-includingregimen.GenotypeswereevaluatedthroughtheStanfordmutation score: patients were ranked for TPV/r and DRV/r resistance as susceptible (class 1), potential lowlevel(class2),low-level(class3),intermediate-level (class4),andhigh-levelresistance(class5).Atbaseline(tipranavirinitiation),thescoringfortipranavir/r was:class3=4(8.5%);class4=31(66%);andclass 5 = 12 (25.5%). Corresponding scores for DRV/r were:class2=1(2%),class3=12(25.5%),class 4 =32(68%),andclass5=2(4.5%).Attipranavir/r virological failure, a shift toward a higher tipranavir/r scoring class was seen in 16 (34.1%) patients (P = 0.001), whereas a shift toward a higher DRV/r scoring class was observed in 9 (19.2%) patients (P = 0.2381). After tipranavir/r virological failure, 25/47 patients (53%) were treated with a DRV/r. After 24 weeks, the median HIV-RNA decrease was 3.04 (2.13-3.45) log 10 copies per milliliter in DRV/rgroupversus−0.04 (−0.44;0.50)log 10 copies per milliliter in patients not treated with a DRV/r (P 0.0001);CD4increasewas126(70-169)cells/mm 3 in DRV/r group versus −42 (−121; 42) not treated withDRV/r(P  0.0001). In conclusion the authors suggest that the treatment with tipranavir/r did not significantly increase the resistance score to DRV/r anddidnotprecludetheefficacyofsubsequenttreatment with his treatment.
44
Conclusions DRV/r is the first of a new generation of PIs and demonstrates potent antiviral activity against wild type strains of HIV-1 and against strains of HIV-1 that areresistanttootherPIs.
The drug has demonstrates efficacy in naïve patient, in induction and maintenance strategy and whenaddedtoanOBTregimeninpatientswhohave experienced treatment failure with multiple drug classes.
First-line DRV/r based regimen may provide the greatest opportunity to fully suppress HIV replication and to prevent the emergence of drug-resistant strains that can lead to treatment failure and compromise future drug treatment options. 24, 25, 39 Hence, first-line ARVregimensshouldbepotentanddurable,prevent ordelaytheonsetofdrugresistance,andhavegood/ excellent tolerability and a convenient dosing schedule.Theresultsofthe48-weekanalysisoftheARTEMIStrialconfirmedthatDRV/rfulfilsthesecriteria, includingthisPIinthecurrentguidelines 4, 6 for use in treatment-naiveHIVpatients.These96-weekresults illustratethattheclinicalresponsetoDRV/risboth significantandpersistent. 39 In HIV-infected population who had experienced virologicalfailure,DRV/rcouldbeaddedtoatleast one new agents from existing classes such as the new NNRTIetravirine, 45, 46 or a new agents of a new class asINIsorCCR5inhibitors. 47, 48 Its high genetic barrierandresistanceprofilemakeitextremelyusefulin patientshavingfailedaPIcontainingregimen.
Disclosures
This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The authors and peer reviewers ofthispaperreportnoconflictsofinterest.
